Numinus (NUMI.TO TSX) earnings Jan 19, 2026 pre-market: watch cash runway
The NUMI.TO stock opens pre-market ahead of Numinus Wellness Inc.’s earnings release on 19 Jan 2026. The share trades at C$0.05 with volume at 989,752 shares and an average volume of 184,378. Investors will focus on cash runway, operating margins and guidance because the company reports results at 12:00 UTC. This earnings spotlight links the numbers to likely price reaction and short-term catalysts for the TSX-listed healthcare name.
NUMI.TO stock pre-market snapshot
Numinus (NUMI.TO) is priced at C$0.05 pre-market and has traded between C$0.05 and C$0.05 today. Year range sits at C$0.03 low and C$0.12 high. Volume is elevated at 989,752, giving relative volume of 5.37 versus average.
NUMI.TO stock earnings details and what to watch
Numinus issues earnings on 19 Jan 2026 at 12:00 UTC and lists EPS of -0.08 on the latest TTM basis. Analysts and traders will watch revenue trends, any cash-flow guidance, and commentary on the Salvation Botanicals and Numinus Health divisions. Management commentary on service demand and regulatory progress typically moves the stock on the TSX.
NUMI.TO stock financials and valuation
The company shows a market cap of C$16,027,581.00 and 320,551,620 shares outstanding. Trailing metrics include a reported PE near -0.63 and price averages: 50-day at C$0.05 and 200-day at C$0.04. Current liquidity is thin; the current ratio is 0.61, and cash per share is C$0.00 (rounded).
Meyka AI rates NUMI.TO with a score out of 100
Meyka AI rates NUMI.TO with a score of 65.87 / 100, grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights modest operational improvement but persistent valuation and liquidity risks on the TSX. These grades are not guaranteed and we are not financial advisors.
NUMI.TO stock risks and opportunities
Risk drivers include negative earnings, low current ratio, and sensitivity to regulatory news. Numinus reports TTM operating cash flow per share of -0.03 and free cash flow per share -0.03, highlighting cash burn concerns. An opportunity is rising demand for psychedelic-assisted therapy and lab services, which could expand revenue if clinical and commercial paths progress.
NUMI.TO stock outlook and sector context
Healthcare sector performance shows muted returns, with the sector down -2.69% over 1 year and YTD up 1.97%, so Numinus will trade relative to peers. Expect volatility around guidance and pipeline updates. Watch intraday moves on TSX and read management commentary for actionable signals.
Final Thoughts
Key takeaways for the NUMI.TO stock earnings event: the share price is C$0.05, EPS is -0.08, and volume is elevated at 989,752. Management commentary on cash and demand should drive the first reaction. Meyka AI’s forecast model projects a near-term scenario target of C$0.08, implying an upside of 60.00% versus the current price of C$0.05, under a constructive operational update. Forecasts are model-based projections and not guarantees. Given the B / HOLD Meyka grade and thin liquidity, investors should size positions carefully and watch guidance and cash-flow statements after the call.
FAQs
When does Numinus report earnings and how will NUMI.TO stock react?
Numinus reports on 19 Jan 2026 at 12:00 UTC. NUMI.TO stock typically reacts to cash guidance, revenue trends, and regulatory updates. Expect higher intraday volatility and volume on an earnings beat or miss.
What are the key financials to check on the NUMI.TO stock report?
Check revenue growth, operating cash flow per share (-0.03 TTM), EPS (-0.08), and cash per share. Also note market cap C$16,027,581.00 and shares outstanding 320,551,620.
What is Meyka AI’s view on NUMI.TO stock after earnings?
Meyka AI assigns a 65.87 / 100 score and a B — HOLD recommendation. The model flags improving metrics but stresses liquidity and valuation risks on the TSX.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
